BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24061862)

  • 1. Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe.
    Noskowicz M; Bogdanova N; Bermisheva M; Takhirova Z; Antonenkova N; Khusnutdinova E; Bremer M; Christiansen H; Park-Simon TW; Hillemanns P; Dörk T
    Fam Cancer; 2014 Jun; 13(2):137-42. PubMed ID: 24061862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
    Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
    BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PALB2 mutations in German and Russian patients with bilateral breast cancer.
    Bogdanova N; Sokolenko AP; Iyevleva AG; Abysheva SN; Blaut M; Bremer M; Christiansen H; Rave-Fränk M; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2011 Apr; 126(2):545-50. PubMed ID: 21165770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.
    Cecener G; Guney Eskiler G; Egeli U; Tunca B; Alemdar A; Gokgoz S; Tasdelen I
    Mol Biol Rep; 2016 Nov; 43(11):1273-1284. PubMed ID: 27573125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
    Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
    Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
    BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo.
    Catucci I; Peterlongo P; Ciceri S; Colombo M; Pasquini G; Barile M; Bonanni B; Verderio P; Pizzamiglio S; Foglia C; Falanga A; Marchetti M; Galastri L; Bianchi T; Corna C; Ravagnani F; Bernard L; Fortuzzi S; Sardella D; Scuvera G; Peissel B; Manoukian S; Tondini C; Radice P
    Genet Med; 2014 Sep; 16(9):688-94. PubMed ID: 24556926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
    Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
    BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PALB2 sequence variants in young South African breast cancer patients.
    Sluiter M; Mew S; van Rensburg EJ
    Fam Cancer; 2009; 8(4):347-53. PubMed ID: 19333784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
    Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
    Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.
    Bogdanova N; Cybulski C; Bermisheva M; Datsyuk I; Yamini P; Hillemanns P; Antonenkova NN; Khusnutdinova E; Lubinski J; Dörk T
    Breast Cancer Res Treat; 2009 Nov; 118(1):207-11. PubMed ID: 18807267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
    Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
    Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast-cancer risk in families with mutations in PALB2.
    Antoniou AC; Casadei S; Heikkinen T; Barrowdale D; Pylkäs K; Roberts J; Lee A; Subramanian D; De Leeneer K; Fostira F; Tomiak E; Neuhausen SL; Teo ZL; Khan S; Aittomäki K; Moilanen JS; Turnbull C; Seal S; Mannermaa A; Kallioniemi A; Lindeman GJ; Buys SS; Andrulis IL; Radice P; Tondini C; Manoukian S; Toland AE; Miron P; Weitzel JN; Domchek SM; Poppe B; Claes KB; Yannoukakos D; Concannon P; Bernstein JL; James PA; Easton DF; Goldgar DE; Hopper JL; Rahman N; Peterlongo P; Nevanlinna H; King MC; Couch FJ; Southey MC; Winqvist R; Foulkes WD; Tischkowitz M
    N Engl J Med; 2014 Aug; 371(6):497-506. PubMed ID: 25099575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline PALB2 truncating mutations in African American breast cancer patients.
    Zheng Y; Zhang J; Niu Q; Huo D; Olopade OI
    Cancer; 2012 Mar; 118(5):1362-70. PubMed ID: 21932393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.